Regeneron Pharmaceuticals (REGN) Assets Average (2010 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Assets Average of $41.3 billion for Q2 2026, up 9.02% year-over-year from $37.9 billion in Q2 2025, and up 1.44% quarter-over-quarter from $40.7 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Assets Average (2010 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Assets Average history runs 17 years deep, the most recent figure standing at $41.3 billion for Q2 2026.
- In Q2 2026, Assets Average rose 9.02% year-over-year to $41.3 billion; the TTM figure through Jun 2026 stood at $41.3 billion (up 9.02% YoY), while the FY2025 annual figure was $39.2 billion, up 10.56% from the prior year.
- Assets Average for Q2 2026 stood at $41.3 billion, up from $40.7 billion in the prior quarter.
- The five-year high for Assets Average was $41.3 billion in Q2 2026, with the low at $25.9 billion in Q1 2022.
- The 5-year median for Assets Average is $34.5 billion (2024), against an average of $34.1 billion.
- The sharpest annual moves came in 2022 and 2025: Assets Average surged 48.23% in 2022, then grew 6.61% in 2025.
- Regeneron Pharmaceuticals' Assets Average stood at $28.4 billion in 2022, then advanced by 14.68% to $32.6 billion in 2023, then grew by 15.26% to $37.6 billion in 2024, then rose by 7.35% to $40.4 billion in 2025, then gained by 2.32% to $41.3 billion in 2026.
- Business Quant data shows REGN's Assets Average at $41.3 billion in Q2 2026, $40.7 billion in Q1 2026, and $40.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.30 Bn |
| Mar 31, 2026 | 40.71 Bn |
| Dec 31, 2025 | 40.36 Bn |
| Sep 30, 2025 | 39.19 Bn |
| Jun 30, 2025 | 37.88 Bn |
| Mar 31, 2025 | 37.65 Bn |
| Dec 31, 2024 | 37.60 Bn |
| Sep 30, 2024 | 36.76 Bn |
| Jun 30, 2024 | 35.23 Bn |
| Mar 31, 2024 | 33.72 Bn |
| Dec 31, 2023 | 32.62 Bn |
| Sep 30, 2023 | 31.41 Bn |
| Jun 30, 2023 | 30.36 Bn |
| Mar 31, 2023 | 29.64 Bn |
| Dec 31, 2022 | 28.45 Bn |
| Sep 30, 2022 | 27.44 Bn |
| Jun 30, 2022 | 26.78 Bn |
| Mar 31, 2022 | 25.89 Bn |
| Dec 31, 2021 | 24.55 Bn |
| Sep 30, 2021 | 22.58 Bn |